Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic–pharmacodynamic relationships
- 261 Downloads
Sarizotan 1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-[[5-(4-fluorophenyl) pyridin-3-yl]methyl] methenamine, showed an in vivo pharmaco-EEG profile resembling that of methylphenidate which is used in attention deficit/hyperactivity disorder (ADHD). In turn, we tested sarizotan against impulsivity in juvenile rats measuring the choice for large delayed vs. a small immediate reward in a T-maze and obtained encouraging results starting at 0.03 mg/kg (plasma levels of ~11 nM). Results from rats treated neonatally with 6-hydroxydopamine (6-OHDA), also supported anti-ADHD activity although starting at 0.3 mg/kg. However, microdialysis studies revealed that free brain concentration of sarizotan at active doses were below its affinity for 5-HT1A receptors, the assumed primary target. In contrast, electrophysiological experiments in mid-brain Raphé serotonergic cells paralleled by plasma sampling showed that there was ~60 % inhibition of firing rate—indicating significant activation of 5-HT1A receptors—at a plasma concentration of 76 nM. In line with this, we observed that sarizotan concentrations in brain homogenates were similar to total blood levels but over 500 fold higher than free extracellular fluid (ECF) concentrations as measured using brain microdialysis. These data suggest that sarizotan may have potential anti-ADHD effects at low doses free of the previously reported side-effects. Moreover, in this case a classical pharmacokinetic–pharmacodynamic relationship based on free brain concentrations seems to be less appropriate than target engagement pharmacodynamic readouts.
Keywords5-HT1A Microdialysis Receptor occupancy Impulsivity EEG In vivo electrophysiology
We would like to thank Anita Vanaga, Christiane Güntner and Werner Feser-Zügner for their support in sarizotan analysis in biological samples and Sabrina David and Sabine Justal for their excellent technical work in the T-maze experiment. Lutz Franke and Barbara Valastro are kindly acknowledged for their contribution to the coordination of experimental activities and providing the idea of ADHD testing respectively.
- Brus R, Kostrzewa RM, Perry KW, Fuller RW (1994) Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment. J Pharmacol Exp Therap 268:231–237Google Scholar
- Gallemann D, Wimmer E, Hofer CC, Freisleben A, Fluck M, Ladstetter B, Dolgos H (2010) In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos 38:905–916CrossRefPubMedGoogle Scholar
- Kuzhikandathil EV, Oxford GS (2002) Classic D1 dopamine receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-13H-benzaze pine hydrochloride (SCH23390) directly inhibits G protein-coupled inwardly rectifying potassium channels. Mol Pharmacol 62:119–126CrossRefPubMedGoogle Scholar
- Leo D, Adriani W, Cavaliere C, Cirillo G, Marco EM, Romano E, di Porzio U, Papa M, Perrone-Capano C, Laviola G (2009) Methylphenidate to adolescent rats drives enduring changes of accumbal Htr7 expression: implications for impulsive behavior and neuronal morphology. Genes Brain Behav 8:356–368CrossRefPubMedGoogle Scholar
- Newman-Tancredi A, Assie MB, Leduc N, Ormiere AM, Danty N, Cosi C (2005) Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8:341–356CrossRefPubMedGoogle Scholar
- Paxinos G, Watson C (1986) The rats brain in stereotaxic coordinates. Academic Press, Nww YorkGoogle Scholar
- Rascol O, Damier P, Goetz C, Hicking C, Hock K, Müller T, Olanow W, Russ H (2006) A large phase III study to evaluate the SAFETY and Efficacy of Sarizotan in the Treatment of Levodopa-induced Dyskinesia Associated with Parkinson´s Disease—the PADDY-1 Study. Movement Disorders. 10th International Congress of Parkinson’s Disease and Movement Disorders, Kyoto, JapanGoogle Scholar
- Valastro B (2012) Sarizotan for use in the treatment of attention deficit hyperactivity disorder (adhd). Google PatentsGoogle Scholar